Publications
-
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.
Hawley S,
Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD.
Adv Anat Pathol.
2013;
20
(1):
39-44
-
Comprehensive gene expression changes associated with mouse postnatal kidney development.
Wu B,
Sahoo D, Brooks JD.
J Urol.
2013;
189
(6):
2385-90
-
Epigenetic changes in histologically normal prostate tissues.
Brooks JD,
J Urol.
2013;
189
(6):
2020-1
-
Identification and Characterization of 2 Testicular Germ Cell Markers, Glut3 and CyclinA2.
Howitt BE,
Brooks JD, Jones S, Higgins JP.
Appl Immunohistochem Mol Morphol.
2013
-
Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1.
Gulzar ZG,
McKenney JK, Brooks JD.
Oncogene.
2013;
32
(1):
70-7
-
Treatment and mortality in men with localized prostate cancer: a population-based study in California.
Sieh W,
Lichtensztajn DY, Nelson DO, Brooks JD, Chang ET.
The Open Prostate Cancer Journal.
2013:
6
1-9
-
Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study.
Lin DW,
Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS.
Clin Cancer Res.
2013;
19
(9):
2442-2450
-
Deficiency in mammalian histone H2B ubiquitin ligase Bre1 (Rnf20/Rnf40) leads to replication stress and chromosomal instability.
Chernikova SB,
Razorenova OV, Higgins JP, Sishc BJ, Nicolau M, Dorth JA, Chernikova DA, Kwok S, Brooks JD, Bailey SM, Game JC, Brown JM.
Cancer Res.
2012;
72
(8):
2111-9
-
Evaluation of SF-1 Expression in Testicular Germ Cell Tumors: A Tissue Microarray Study of 127 Cases.
Sangoi AR,
McKenney JK, Brooks JD, Higgins JP.
Appl Immunohistochem Mol Morphol.
2012
-
Evaluation of putative renal cell carcinoma markers PAX-2, PAX-8, and hKIM-1 in germ cell tumors: a tissue microarray study of 100 cases.
Sangoi AR,
McKenney JK, Brooks JD, Bonventre JV, Higgins JP.
Appl Immunohistochem Mol Morphol.
2012;
20
(5):
451-3
-
Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence.
Truong M,
Yang B, Wagner J, Kobayashi Y, Rajamanickam V, Brooks J, Jarrard DF.
Br J Cancer.
2012;
107
(1):
100-7
-
Gene expression changes induced by unilateral ureteral obstruction in mice.
Wu B,
Brooks JD.
J Urol.
2012;
188
(3):
1033-41
-
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
King CR,
Brooks JD, Gill H, Presti JC.
Int J Radiat Oncol Biol Phys.
2012;
82
(2):
877-82
-
Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology.
Kimm SY,
Tarin TV, Lee JH, Hu B, Jensen K, Nishimura D, Brooks JD.
J Magn Reson Imaging.
2012;
36
(1):
206-12
-
Performance characteristics of prostate-specific antigen in patients undergoing radical prostatectomy.
Liu JJ,
Ferrari M, Nolley R, Brooks JD, Presti JC.
Urology.
2012;
79
(6):
1336-9
-
Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness.
Huang S,
Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack JR.
Oncogene.
2012;
31
(37):
4164-70
-
Translational genomics: the challenge of developing cancer biomarkers.
Brooks JD,
Genome Res.
2012;
22
(2):
183-7
-
mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer.
Cann GM,
Gulzar ZG, Cooper S, Li R, Luo S, Tat M, Stuart S, Schroth G, Srinivas S, Ronaghi M, Brooks JD, Talasaz AH.
PLoS One.
2012;
7
(11):
e49144
-
Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival.
Chung BI,
Tarin TV, Ferrari M, Brooks JD.
Urol Oncol.
2011 May-Jun;
29
(3):
314-8
-
A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer.
Malhotra S,
Lapointe J, Salari K, Higgins JP, Ferrari M, Montgomery K, van de Rijn M, Brooks JD, Pollack JR.
PLoS One.
2011;
6
(5):
e20293
-
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer.
Kobayashi Y,
Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G.
Genome Res.
2011;
21
(7):
1017-27
-
Integrated genomic analyses of ovarian carcinoma.
Nature.
2011;
474
(7353):
609-15
-
Length of site-specific positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy.
Hsu M,
Chang SL, Ferrari M, Nolley R, Presti Jr JC, Brooks JD.
Int J Urol.
2011
-
Small prostate size and high grade disease--biology or artifact?
Liu JJ,
Brooks JD, Ferrari M, Nolley R, Presti JC.
J Urol.
2011;
185
(6):
2108-11
-
Smoking and adverse outcomes at radical prostatectomy.
Ngo TC,
Lee JJ, Brooks JD, Nolley R, Ferrari M, Presti Jr JC.
Urol Oncol.
2011
-
Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases.
Sangoi AR,
Karamchandani J, Lane B, Higgins JP, Rouse RV, Brooks JD, McKenney JK.
Mod Pathol.
2011;
24
(3):
425-9
-
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study.
McKenney JK,
Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD.
J Urol.
2011;
186
(2):
465-9
-
Adjuvant docetaxel and abbreviated androgen deprivation therapy in patients with high risk prostate cancer
Bazan JG,
King CR, Brooks JD, Srinivas S.
The Open Prostate Cancer Journal.
2010:
3
99-104
-
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.
Newcomb LF,
Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW.
Urology.
2010;
75
(2):
407-13
-
Gene expression changes induced by genistein in the prostate cancer cell line LNCaP
Bhamre S,
Sahoo D, Tibshirani R, Dill DL, Brooks JD.
The Open Prostate Cancer Journal.
2010:
3
86-98
-
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns.
Brannon AR,
Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, Rathmell WK.
Genes Cancer.
2010;
1
(2):
152-163
-
The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis.
Quick CM,
Gokden N, Sangoi AR, Brooks JD, McKenney JK.
Hum Pathol.
2010;
41
(8):
1145-9
-
Prognostic significance of prostate cancer originating from the transition zone.
King CR,
Ferrari M, Brooks JD.
Urol Oncol.
2009 Nov-Dec;
27
(6):
592-7
-
Alteration of gene expression signatures of cortical differentiation and wound response in lethal clear cell renal cell carcinomas.
Zhao H,
Zongming Ma, Tibshirani R, Higgins JP, Ljungberg B, Brooks JD.
PLoS One.
2009;
4
(6):
e6039
-
Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen insensitivity syndrome.
Appari M,
Werner R, Wünsch L, Cario G, Demeter J, Hiort O, Riepe F, Brooks JD, Holterhus PM.
J Mol Med (Berl).
2009;
87
(6):
623-32
-
CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.
Williams AA,
Higgins JP, Zhao H, Ljunberg B, Brooks JD.
BMC Clin Pathol.
2009:
9
9
-
Disorders of sex development expose transcriptional autonomy of genetic sex and androgen-programmed hormonal sex in human blood leukocytes.
Holterhus PM,
Bebermeier JH, Werner R, Demeter J, Richter-Unruh A, Cario G, Appari M, Siebert R, Riepe F, Brooks JD, Hiort O.
BMC Genomics.
2009:
10
292
-
Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients.
Swami S,
Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, Brooks JD, Peehl DM, Feldman D.
Int J Cancer.
2009;
124
(9):
2050-9
-
Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation.
Gardner CD,
Oelrich B, Liu JP, Feldman D, Franke AA, Brooks JD.
Prostate.
2009;
69
(7):
719-26
-
Recommendations for the reporting of surgically resected specimens of renal cell carcinoma.
Am J Clin Pathol.
2009;
131
(5):
623-30
-
Recommendations for the reporting of surgically resected specimens of renal cell carcinoma: the Association of Directors of Anatomic and Surgical Pathology.
Higgins JP,
McKenney JK, Brooks JD, Argani P, Epstein JI.
Hum Pathol.
2009;
40
(4):
456-63
-
Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR,
Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC.
Int J Radiat Oncol Biol Phys.
2009;
73
(4):
1043-8
-
Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells.
Bhamre S,
Sahoo D, Tibshirani R, Dill DL, Brooks JD.
Prostate.
2009;
69
(2):
181-90
-
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature.
2008;
455
(7216):
1061-8
-
Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle.
Thompson M,
Lapointe J, Choi YL, Ong DE, Higgins JP, Brooks JD, Pollack JR.
Prostate.
2008;
68
(11):
1248-56
-
Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
King CR,
Presti JC, Brooks JD, Gill H, Spiotto MT.
Int J Radiat Oncol Biol Phys.
2008;
70
(5):
1472-7
-
The impact of tumor volume on outcomes after radical prostatectomy: Implications for prostate cancer screening.
James D. Brooks,
Robert Tibshirani, Michelle Ferrari, Joseph C. Presti, Jr., Harcharan Gill, Christopher R. King.
The Open Prostate Cancer Journal.
2008:
1
1-8
-
hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.
Lapointe J,
Malhotra S, Higgins JP, Bair E, Thompson M, Salari K, Giacomini CP, Ferrari M, Montgomery K, Tibshirani R, van de Rijn M, Brooks JD, Pollack JR.
Am J Surg Pathol.
2008;
32
(2):
205-9
-
A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells.
Li TH,
Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z.
Nucleic Acids Res.
2007;
35
(8):
2767-76
-
A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.
Lapointe J,
Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR.
Mod Pathol.
2007;
20
(4):
467-73
-
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.
Zhao H,
Ramos CF, Brooks JD, Peehl DM.
J Cell Physiol.
2007;
210
(1):
111-21
-
Editorial Comments.
Brooks JD,
J Urol.
2007;
178
(6):
2400
-
Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor.
Pflug BR,
Zheng H, Udan MS, D'Antonio JM, Marshall FF, Brooks JD, Nelson JB.
Cancer Lett.
2007;
246
(1-2):
139-48
-
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.
Lapointe J,
Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR.
Cancer Res.
2007;
67
(18):
8504-10
-
Intrinsic androgen-dependent gene expression patterns revealed by comparison of genital fibroblasts from normal males and individuals with complete and partial androgen insensitivity syndrome.
Holterhus PM,
Deppe U, Werner R, Richter-Unruh A, Bebermeier JH, Wünsch L, Krege S, Schweikert HU, Demeter J, Riepe F, Hiort O, Brooks JD.
BMC Genomics.
2007:
8
376
-
Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP,
Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, Marinelli RJ, Presti JC, van de Rijn M, Brooks JD.
Am J Surg Pathol.
2007;
31
(5):
673-80
-
Selenomethionine induced transcriptional programs in human prostate cancer cells.
Zhao H,
Brooks JD.
J Urol.
2007;
177
(2):
743-50
-
The application of genomic and proteomic approaches to human prostate cancer in developing diagnostic and prognostic markers.
Brooks JD,
Urol Oncol.
2006 May-Jun;
24
(3):
222-3
-
Application of genomic technologies to human prostate cancer.
Li S,
Bhamre S, Lapointe J, Pollack JR, Brooks JD.
OMICS.
2006;
10
(3):
261-75
-
Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription.
Bebermeier JH,
Brooks JD, DePrimo SE, Werner R, Deppe U, Demeter J, Hiort O, Holterhus PM.
J Mol Med (Berl).
2006;
84
(11):
919-31
-
Editorial comment.
Brooks JD,
J Urol.
2006;
176
(5):
2005
-
Editorial comment.
Brooks JD,
J Urol.
2006;
175
(2):
472-3
-
Gene expression profiling predicts survival in conventional renal cell carcinoma.
Zhao H,
Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD.
PLoS Med.
2006;
3
(1):
e13
-
Modest induction of phase 2 enzyme activity in the F-344 rat prostate.
Jones SB,
Brooks JD.
BMC Cancer.
2006:
6
62
-
Refractory hematuria from amyloidosis successfully treated by splenectomy.
Ma JF,
Coutre SE, Curet MJ, Brooks JD.
Urology.
2006;
67
(5):
1085.e13-5
-
Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade.
King CR,
McNeal JE, Gill H, Brooks JD, Srinivas S, Presti JC.
Urology.
2006;
67
(6):
1229-34
-
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Zhao H,
Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack JR, Brooks JD.
Prostate.
2005;
63
(2):
187-97
-
Juvenile posttraumatic high-flow priapism: current management dilemmas.
Marotte JB,
Brooks JD, Sze D, Kennedy WA.
J Pediatr Surg.
2005;
40
(4):
E25-8
-
Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer.
Zhang H,
Dong Y, Zhao H, Brooks JD, Hawthorn L, Nowak N, Marshall JR, Gao AC, Ip C.
Cancer Genomics Proteomics.
2005;
2
(2):
97-114
-
Molecular targets of doxazosin in human prostatic stromal cells.
Zhao H,
Lai F, Nonn L, Brooks JD, Peehl DM.
Prostate.
2005;
62
(4):
400-10
-
Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy.
Lee KL,
Marotte JB, Ferrari MK, McNeal JE, Brooks JD, Presti JC.
Urology.
2005;
65
(2):
311-5
-
Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy.
Patel DA,
Presti JC, McNeal JE, Gill H, Brooks JD, King CR.
J Clin Oncol.
2005;
23
(25):
6157-62
-
Reg IV: a promising marker of hormone refractory metastatic prostate cancer.
Gu Z,
Rubin MA, Yang Y, Deprimo SE, Zhao H, Horvath S, Brooks JD, Loda M, Reiter RE.
Clin Cancer Res.
2005;
11
(6):
2237-43
-
Resveratrol-induced gene expression profiles in human prostate cancer cells.
Jones SB,
DePrimo SE, Whitfield ML, Brooks JD.
Cancer Epidemiol Biomarkers Prev.
2005;
14
(3):
596-604
-
The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer.
Kim H,
Lapointe J, Kaygusuz G, Ong DE, Li C, van de Rijn M, Brooks JD, Pollack JR.
Cancer Res.
2005;
65
(18):
8118-24
-
Time trends in pathologic features of radical prostatectomy--impact of family history.
Marotte JB,
Ferrari MK, McNeal JE, Brooks JD, Presti JC.
Urol Oncol.
2004 May-Jun;
22
(3):
169-73
-
A transcriptional profile of aging in the human kidney.
Rodwell GE,
Sonu R, Zahn JM, Lund J, Wilhelmy J, Wang L, Xiao W, Mindrinos M, Crane E, Segal E, Myers BD, Brooks JD, Davis RW, Higgins J, Owen AB, Kim SK.
PLoS Biol.
2004;
2
(12):
e427
-
Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.
Krishnan AV,
Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D.
Prostate.
2004;
59
(3):
243-51
-
Biochemical remission after resection of prostate cancer lung metastasis.
Chao DH,
Higgins JP, Brooks JD.
Urology.
2004;
63
(3):
584-5
-
Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells.
Zhao H,
Whitfield ML, Xu T, Botstein D, Brooks JD.
Mol Biol Cell.
2004;
15
(2):
506-19
-
Gene expression in the normal adult human kidney assessed by complementary DNA microarray.
Higgins JP,
Wang L, Kambham N, Montgomery K, Mason V, Vogelmann SU, Lemley KV, Brown PO, Brooks JD, van de Rijn M.
Mol Biol Cell.
2004;
15
(2):
649-56
-
Gene expression profiling identifies clinically relevant subtypes of prostate cancer.
Lapointe J,
Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR.
Proc Natl Acad Sci U S A.
2004;
101
(3):
811-6
-
Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population.
Presti JC,
Lee U, Brooks JD, Terris MK.
J Urol.
2004;
171
(6 Pt 1):
2199-202
-
Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis.
Peehl DM,
Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, Feldman D.
J Steroid Biochem Mol Biol.
2004;
92
(3):
131-41
-
Radiotherapy after radical prostatecomy: Does transient androgen suppression improve outcomes?
King C,
Presti J, Gill H, Brooks J, Hancock S.
International Journal of Radiation Oncology Biology Physics.
2004:
59
341-347
-
Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables.
Ferrari MK,
McNeal JE, Malhotra SM, Brooks JD.
Urology.
2004;
64
(4):
749-53
-
Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen.
Shinghal R,
Yemoto C, McNeal JE, Brooks JD.
Urology.
2003;
61
(2):
380-5
-
Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen receptor.
Holterhus PM,
Hiort O, Demeter J, Brown PO, Brooks JD.
Genome Biol.
2003;
4
(6):
R37
-
Expression of FKBP12 in benign and malignant vascular endothelium: an immunohistochemical study on conventional sections and tissue microarrays.
Higgins JP,
Montgomery K, Wang L, Domanay E, Warnke RA, Brooks JD, van de Rijn M.
Am J Surg Pathol.
2003;
27
(1):
58-64
-
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors.
Sperger JM,
Chen X, Draper JS, Antosiewicz JE, Chon CH, Jones SB, Brooks JD, Andrews PW, Brown PO, Thomson JA.
Proc Natl Acad Sci U S A.
2003;
100
(23):
13350-5
-
Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray.
Higgins JP,
Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, Brooks JD.
Am J Pathol.
2003;
162
(3):
925-32
-
Anatomy of the rectourethralis muscle.
Brooks JD,
Eggener SE, Chao WM.
Eur Urol.
2002;
41
(1):
94-100
-
Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro.
Brooks JD,
Goldberg MF, Nelson LA, Wu D, Nelson WG.
Cancer Epidemiol Biomarkers Prev.
2002;
11
(9):
868-75
-
Microarray analysis in prostate cancer research.
Brooks JD,
Curr Opin Urol.
2002;
12
(5):
395-9
-
Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells.
Schwarze SR,
DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF.
J Biol Chem.
2002;
277
(17):
14877-83
-
Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis.
Shibata A,
Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, Henderson S, Yemoto CE, Peehl DM.
Prostate.
2002;
52
(4):
269-78
-
Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells.
Vidanes GM,
Paton V, Wallen E, Peehl DM, Navone N, Brooks JD.
Prostate.
2002;
51
(4):
225-30
-
Transcriptional programs activated by exposure of human prostate cancer cells to androgen.
DePrimo SE,
Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD.
Genome Biol.
2002;
3
(7):
RESEARCH0032
-
GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells.
Lin X,
Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, Bova GS, Isaacs WB, Brooks JD, DeWeese TL, De Marzo AM, Nelson WG.
Am J Pathol.
2001;
159
(5):
1815-26
-
New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents.
Williams ED,
Brooks JD.
Urology.
2001;
57
(4 Suppl 1):
100-2
-
Plasma selenium level before diagnosis and the risk of prostate cancer development.
Brooks JD,
Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB.
J Urol.
2001;
166
(6):
2034-8
-
Potent induction of phase 2 enzymes in human prostate cells by sulforaphane.
Brooks JD,
Paton VG, Vidanes G.
Cancer Epidemiol Biomarkers Prev.
2001;
10
(9):
949-54
-
Preneoplastic prostate lesions: an opportunity for prostate cancer prevention.
Nelson WG,
De Marzo AM, Deweese TL, Lin X, Brooks JD, Putzi MJ, Nelson CP, Groopman JD, Kensler TW.
Ann N Y Acad Sci.
2001:
952
135-44
-
Prevention of prostate cancer.
DePrimo SE,
Shinghal R, Vidanes G, Brooks JD.
Hematol Oncol Clin North Am.
2001;
15
(3):
445-57
-
Role of cytologic criteria in the histologic diagnosis of Gleason grade 1 prostatic adenocarcinoma.
McNeal JE,
Cohen RJ, Brooks JD.
Hum Pathol.
2001;
32
(4):
441-6
-
GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas.
Tchou JC,
Lin X, Freije D, Isaacs WB, Brooks JD, Rashid A, De Marzo AM, Kanai Y, Hirohashi S, Nelson WG.
Int J Oncol.
2000;
16
(4):
663-76
-
Absence of HinfI Restriction Abnormalities in Renal Oncocytoma Mitochondrial DNA.
Brooks JD,
Marshall FF, Isaacs WB, Johns DR.
Mol Urol.
1999;
3
(1):
1-3
-
Partial nephrectomy and caval thrombectomy for renal cell carcinoma in a solitary kidney with an accessory renal vein.
Pruthi RS,
Angell SK, Brooks JD, Gill H.
BJU Int.
1999;
83
(1):
142-3
-
Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent.
Brooks JD,
Paton V.
Prostate Cancer Prostatic Dis.
1999;
2
(S3):
S8
-
CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia.
Brooks JD,
Weinstein M, Lin X, Sun Y, Pin SS, Bova GS, Epstein JI, Isaacs WB, Nelson WG.
Cancer Epidemiol Biomarkers Prev.
1998;
7
(6):
531-6
-
Male pelvic anatomy reconstructed from the visible human data set.
Brooks JD,
Chao WM, Kerr J.
J Urol.
1998;
159
(3):
868-72
-
Differentiation of colonic metaplasia from adenocarcinoma of urinary bladder.
Jacobs LB,
Brooks JD, Epstein JI.
Hum Pathol.
1997;
28
(10):
1152-7
-
Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer.
Nelson JB,
Lee WH, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG, Bova GS.
Cancer Res.
1997;
57
(1):
35-7
-
The Swedish prostate cancer paradox.
Walsh PC,
Brooks JD.
JAMA.
1997;
277
(6):
497-8
-
An uncertain role for p53 gene alterations in human prostate cancers.
Brooks JD,
Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB.
Cancer Res.
1996;
56
(16):
3814-22
-
Epidemiologic and molecular features of prostate carcinogenesis as clues for new prostate cancer prevention strategies
Brooks JD,
Lee WH, Nelson WG.
Canadian Journal of Urology.
1996;
3
(Supplement):
30-36
-
Molecular staging of prostate cancer
Lee WH,
Brooks JD, Nelson WG.
Canadian Journal of Urology.
1996;
3
(Supplement):
80-88
-
Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas.
Brooks JD,
Bova GS, Isaacs WB.
Prostate.
1995;
26
(1):
35-9
-
Comparison of open and endourologic approaches to the obstructed ureteropelvic junction.
Brooks JD,
Kavoussi LR, Preminger GM, Schuessler WW, Moore RG.
Urology.
1995;
46
(6):
791-5
-
Embryonal adenoma of the kidney: case report
Perlman EJ,
Brooks J, Gordon AH, Griffin CA, Schoenberg M.
Journal of Urology.
1995:
154
1473-1474
-
Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney.
Schoenberg M,
Cairns P, Brooks JD, Marshall FF, Epstein JI, Isaacs WB, Sidransky D.
Genes Chromosomes Cancer.
1995;
12
(1):
76-80
-
Molecular and chromosomal alterations in prostate cancer.
Isaacs WB,
Bova GS, Morton R, Bussemakers MJG, Brooks JD, Ewing CM.
Cancer.
1995:
75
2004-2012
-
Molecular biology of prostate cancer progression.
Isaacs WB,
Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM.
Cancer Surv.
1995:
23
19-32
-
UPJ obstruction: assessing minimally invasive therapies.
Moore RG,
Brooks JD.
Contemp Urol.
1995;
7
(12):
47-9, 54-5, 59-61
-
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.
Lee WH,
Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG.
Proc Natl Acad Sci U S A.
1994;
91
(24):
11733-7
-
Genetic alterations in prostate cancer.
Isaacs WB,
Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM.
Cold Spring Harb Symp Quant Biol.
1994:
59
653-9
-
Laparoscopic management of testicular pain after embolotherapy of varicocele.
Brooks JD,
Moore RG, Kavoussi LR.
J Endourol.
1994;
8
(5):
361-3
-
Molecular biology of prostate cancer.
Isaacs WB,
Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM.
Semin Oncol.
1994;
21
(5):
514-21
-
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra JR,
Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Braunch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, Linehan WM.
Nature Genetics.
1994:
7
85-90
-
Genetic alterations in prostate cancer - prognostic implications?
Isaacs WB,
Bova GS, Brooks JD, Ewing CM, Morton RA, Robinson JC.
Akteulle Onkologie.
1993:
78
84-92
-
Regional DNA Hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors
Makos M,
Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W, Linehan M, Baylin SB.
Cancer Research.
1993:
53
2719-2722
-
Tubularized neourethra following radical retropubic prostatectomy.
Steiner MS,
Burnett AL, Brooks JD, Brendler CB, Stutzman RE, Carter HB.
J Urol.
1993;
150
(2 Pt 1):
407-9; discussion 409-10
-
Tumor suppressor gene allelic loss in human renal cancers.
Brooks JD,
Bova GS, Marshall FF, Isaacs WB.
J Urol.
1993;
150
(4):
1278-83
-
Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum.
Ricaurte GA,
Langston JW, DeLanney LE, Irwin I, Brooks JD.
Neurosci Lett.
1985;
59
(3):
259-64
Help